• Publications
  • Influence
Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.
Although the role of the renin-angiotensin system in the pathogenesis of hypertension remains a subject of active investigation and debate, there is increasing recognition that pharmacologicalExpand
  • 370
  • 4
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.
We investigated the antihypertensive effect of the angiotensin converting-enzyme inhibitor SQ 14225 in 12 hypertensive patients for periods of three to 24 weeks. Blood pressure decreased in allExpand
  • 591
  • 3
A New Class of Diuretic-Saluretic Agents, The α, β-Unsaturated Ketone Derivatives of Aryloxyacetic Acids
Summary 1. The diuretic-saluretic properties of a new series of compounds, the α, β-unsaturated ketone derivatives of aryloxyacetic acids, have been described. 2. These compounds cause a prompt andExpand
  • 26
  • 2
Disposition of captopril in normal subjects
The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg tablet of 35S‐labeled drug.Expand
  • 154
  • 1
Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.
Azthreonam, a monocyclic beta-lactam highly active against aerobic gram-negative bacteria in vitro, was administered to four groups of nine healthy male volunteers in the following four regimens: 500Expand
  • 40
  • 1
Pharmacokinetics of Captopril in Elderly Healthy Male Volunteers
The pharmacokinetics of captopril were studied in 12 healthy male volunteers aged 65 to 76 years, who each received a single 100‐mg oral dose. Blood and urine samples were collected over a 24‐hourExpand
  • 26
  • 1
Captopril kinetics
Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was given by mouth and intravenously in 10‐mg doses to five healthy subjects. After intravenous dosing,Expand
  • 44
  • 1
Interruption of the Renin‐Angiotensin System in Hypertensive Patients by Captopril Induces Sustained Reduction in Aldosterone Secretion, Potassium Retention and Natriuresis
SUMMARY The orally active angiotensin converting enzyme inhibitor, captopril, was administered to 23 hypertensive patients maintained for 10 days on a constant sodium and potassium intake. BecauseExpand
  • 185
  • PDF
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.
The antihypertensive effect of the orally active angiotensin-converting enzyme inhibitor captopril (SQ 14225) was assessed in 22 hypertensive patients of whom 17 were followed for periods rangingExpand
  • 367